Supplier, CDMO, and inventory management

This article addresses the two sources of supply you can most directly document today, which are the supply you procure from external partners and the supply you already hold as inventory. Together, supplier and CDMO management on one side and inventory management on the other account for the majority of the supply picture in most biologics and ATMP organizations, and the majority of the avoidable surprises.

The discipline here is data hygiene, not heroics. Cycle times must be captured, monitored, and treated as living inputs. CDMO relationships must be governed through structured communication and a forward-looking forecast. Inventory must be set from real cycle-time data and watched continuously for expiry. Done well, they make the supply you buy and hold a dependable input to the plan. Neglected, they pass their errors into every downstream calculation.

Supplier management

A supply plan is only as good as its assumptions about supplier performance. The first obligation of supply planning is therefore to understand all sources of supply for your therapy at every level of the Bill of Material, from starting materials, through in-process intermediates, to formulated drug product. In this sector, BOMs are frequently multi-tier and populated with custom, single-sourced, or sole-sourced components, which makes supplier visibility a planning imperative rather than a procurement nicety.

For every manufactured material, planners must capture and monitor three cycle times, which are manufacturing, release, and transit, with transit including demonstrated customs clearance for international movements. These figures feed stock-setting strategy and delivery commitments directly, so they need regular review rather than a one-time setup. When they are stale, every safety stock target and every promised date built on them is wrong.

• Treat cycle times as living data, documenting and monitoring manufacturing, release, and transit cycle times, including customs clearance, at every BOM level.
• Develop KPIs to track supplier performance against agreed cycle times. A deviation is an early warning of supply risk, visible before it becomes a shortage.
• Flag the risky sources by identifying which materials are custom, single-sourced, or sole-sourced. These carry the most concentrated risk and deserve the closest monitoring.

CDMO governance at scale

For most biologics and ATMP companies, the Contract Development and Manufacturing Organization is the single most critical node in the supply network. The quality of the planning relationship, not merely the contractual terms, determines whether this source of supply behaves predictably. Governance should therefore be deliberate and tiered.

Establish at least two levels of governance operating at different cadences, with an executive tier focused on strategic alignment and relationship health and a tactical tier focused on forecast review, schedule management, and issue resolution. Provide the CDMO with a rolling forecast extending at least 36 months into the future and update it at regular intervals, so that capacity allocation decisions can be made with adequate lead time. Visibility drives trust, and trust is what converts reserved capacity into reliable supply.

• Run two governance tiers with distinct cadences, an executive review (for example, quarterly or twice a year) and a tactical review aligned to the monthly S&OP.
• Share a rolling 36-month forecast, updated at every planning cycle. Withholding forward visibility introduces self-imposed supply risk.
• Develop mutually agreed KPIs, reported consistently to the appropriate stakeholder levels on both sides of the relationship.
• Incentivize the right outcomes. Reward optimization of material cost or the maintenance of agreed inventory levels with a fee or incentive, aligning the CDMO’s behavior with your supply and cost goals.

Inventory management

Inventory is where the supply-demand tension becomes tangible. Too little, and you face shortfalls and delayed patient access. Too much, and you carry costly write-off risk from material that expires before it can be used. In biologics and ATMPs, where shelf lives are often short, material costs extraordinarily high, and autologous therapies leave no room for substitution, getting inventory right is not optional.

Inventory setting strategies must be built from the bottom up, using actual manufacturing and release cycle-time data at each BOM level. Supplier cycle-time accuracy matters because your stock targets are calculated directly from those numbers. For inbound materials, work with Engineering and Quality to document the qualities that introduce risk (custom materials, single- or sole-sourced items, and materials susceptible to contamination) so that stock strategy reflects real exposure rather than an averaged assumption.

• Develop inventory setting strategies at each BOM level from cycle-time data, and revise them whenever the underlying cycle-time assumptions change.
• Document risk-bearing qualities of inbound materials with Engineering and Quality. Custom, single-sourced, and sole-sourced items warrant higher coverage.
• Report inventory levels and exposure as a standing agenda item in the S&OP process, so issues surface before something breaks.

As inventory strategy is set, also capture the total acquisition cost (TAC) of held material, including vendor price, transportation, release testing, documentation, holding cost, tariffs, and other taxes. Increasing inventory can temporarily buffer a shortage, but it is a financially inefficient mitigation because of upfront cost and expiry risk. Knowing the true cost of a held unit keeps that trade-off honest.

Tagging supply by status

Beyond quantity, timing, and risk, every source of supply must be characterized by its qualification and phase status, because certain demands can be satisfied only by certain supply. Post-PPQ material, registered commercial lots, and pre-PPQ or engineering material are not interchangeable even at the same BOM level and in the same UOM. Clinical demand for pivotal and Phase 3 studies typically requires post-PPQ material, while commercial demand requires registered, process-validated supply of the correct process version and manufacturing site.

• Tag each inventory lot and each inbound source with its qualification status (pre-PPQ or engineering, post-PPQ, or registered commercial) along with its process version and manufacturing site.
• Record the eligible supply status for each demand stream, so that, at balancing, supply is netted only against the demand it is qualified to satisfy.

This characterization is captured while gathering supply. The netting rules that enforce it, and prevent an ineligible source from being counted as available supply, are applied when supply and demand are balanced.

Bringing the procured and held picture together

Supplier management and inventory management answer the same question from two sides, which is what supply you can count on, and when. Answered together, they produce the first two lines of the unified supply picture. The first is inbound procurement phased across the horizon by reliable cycle times, and the second is on-hand inventory netted for expiry. Both must be expressed in the agreed UOM at the agreed BOM level so they can later be summed with capacity and balanced against demand.

Part 3 completes the picture with the third source of supply, manufacturing capacity, and the planning-horizon agreements that make all three sources into a shared commitment rather than a supply-chain artifact. It then shows how the consolidated supply view is netted against demand to enable genuine supply-demand balancing.